Last reviewed · How we verify
Alzaten (phentetramine)
Alzaten (generic name: phentetramine) is a phentetramine drug. It is currently in unknown development.
Phentetramine is thought to work by activating certain receptors in the brain to increase the release of neurotransmitters.
Alzaten, also known as phentetramine, is a small molecule drug in the phentetramine class. Unfortunately, there is limited information available on this compound. It is not clear what specific target it binds to or what indications it is approved for. Alzaten's commercial status and safety considerations are also unknown. Further research is needed to fully understand this compound.
At a glance
| Generic name | phentetramine |
|---|---|
| Drug class | phentetramine |
| Therapeutic area | Neuroscience |
| Phase | unknown |
Mechanism of action
Imagine your brain is a city with different neighborhoods. Phentetramine is like a key that unlocks certain neighborhoods, allowing more messages to be sent between them. This can help improve communication between different parts of the brain.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Alzaten CI brief — competitive landscape report
- Alzaten updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Alzaten
What is Alzaten?
How does Alzaten work?
What is the generic name of Alzaten?
What drug class is Alzaten in?
What development phase is Alzaten in?
Related
- Drug class: All phentetramine drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing